Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

This biotech has a powerful growth story, but one competitive threat could reshape the entire investment case before the ...

CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group ...

Michael Yee, UBS biotech analyst, joins 'The Exchange' to discuss Yee's thoughts on biotech stocks, what's driving the ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Biotech is the story at midday Friday, and it’s not a pretty one for shareholders who chased the sector’s monster 2026 run.

The recent rally in biotechnology stocks is being driven by improving fundamentals and a resurgence in merger activity rather than speculative excess, according to Jonathan Faison, founder of ROTY ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

Biotech is now the deepest pocket of leadership in the entire Nasdaq. Everyone can see biotech is moving, and the why is ...

Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.

Another wave of layoffs has hit one of the Bay Area's biggest biotech companies—and the latest cuts push a troubling trend ...

July 10 (Reuters) - Apnimed, a late-stage clinical pharmaceutical company, filed for an initial public offering in the U.S. on Friday. The biotech sector has staged a notable comeback as fresh capital ...